Skye Bioscience (SKYE) Cash & Equivalents (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Cash & Equivalents of $8.1 million for Q1 2026, down 82.45% year-over-year from $46.4 million in Q1 2025, and up 38.53% quarter-over-quarter from $5.9 million in Q4 2025.
Skye Bioscience (SKYE) Cash & Equivalents (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Cash & Equivalents for 15 consecutive years, with $8.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents fell 82.45% year-over-year to $8.1 million; the TTM figure through Mar 2026 stood at $8.1 million (down 82.45% YoY), while the FY2025 annual figure was $5.9 million, down 91.4% from the prior year.
- Cash & Equivalents advanced to $8.1 million in Q1 2026 per SKYE's latest filing, from $5.9 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $83.3 million in Q1 2024 and bottomed at $4572.0 in Q1 2022.
- Historically, Cash & Equivalents has averaged $23.9 million across 5 years, with a median of $8.1 million in 2026.
- Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 99.91% — and 2024, when it soared 1817233.34%.
- Skye Bioscience's Cash & Equivalents stood at $4580.0 in 2022, then jumped by 27333.47% to $1.3 million in 2023, then surged by 5345.15% to $68.4 million in 2024, then sank by 91.4% to $5.9 million in 2025, then jumped by 38.53% to $8.1 million in 2026.
- Business Quant data shows SKYE's Cash & Equivalents at $8.1 million in Q1 2026, $5.9 million in Q4 2025, and $18.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - | 8.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.15 Mn |
| Dec 31, 2025 | 5.88 Mn |
| Sep 30, 2025 | 18.44 Mn |
| Jun 30, 2025 | 23.84 Mn |
| Mar 31, 2025 | 46.42 Mn |
| Dec 31, 2024 | 68.42 Mn |
| Sep 30, 2024 | 67.41 Mn |
| Jun 30, 2024 | 74.12 Mn |
| Mar 31, 2024 | 83.34 Mn |
| Dec 31, 2023 | 1.26 Mn |
| Sep 30, 2023 | 9.08 Mn |
| Jun 30, 2023 | 553,443.00 |
| Mar 31, 2023 | 4,586.00 |
| Dec 31, 2022 | 4,580.00 |
| Sep 30, 2022 | 4,574.00 |
| Jun 30, 2022 | 4,573.00 |
| Mar 31, 2022 | 4,572.00 |
| Sep 30, 2021 | 4,570.00 |
| Jun 30, 2021 | 5.19 Mn |
| Mar 31, 2021 | 4,567.00 |